Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 297

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 297
---
|---------:|:--|:----|:--|-------------:|:--|
| Principal amount |     | $ |    1,350 |   |     | $ |        1,350 |   |
| Discount rate    |     |   |       30 | % |     |   |           30 | % |
| Term (years)     |     |   |     0.25 |   |     |   |         0.40 |   |
| Fair value       |     | $ |    7,112 |   |     | $ |        4,372 |   |

The Company has performed a sensitivity
analysis of the 2020 Notes which are classified as level 3 financial instruments in the fair value hierarchy. The Company recalculated
the fair value of the 2020 Notes by applying a +/- 5.0% changes to the discount rate used in PWERM.

As of June 30, 2025, a 5.0% decrease
in discount rate would increase the fair value of the 2020 Notes to $7,183; a 5.0% increase in discount rate would decrease the fair
value of the 2020 Notes to $7,045.

The following table presents changes
in the fair value of the 2020 Notes and 2021 Notes:

| Balance as of January 1, 2025 |     | $ | 4,372 |
| Changes in fair value         |     |   | 2,740 |
| Balance as of June 30, 2025   |     | $ | 7,112 |

| Balance               
 as of January 1, 2024 |     | $ |  7,405 |   |
| Changes               
 in fair value         |     |   | (4,867 | ) |
| Balance               
 as of June 30, 2024   |     | $ |  2,538 |   |

| NOTE 6: | WARRANT LIABILITY |

During 2015, the Company issued
167,365 warrants in connection with the issuance of its convertible notes, which are exercisable into convertible preferred D-2 shares
at an exercise price of $15.20 per share. The warrants were exercisable at the earlier of: (i) March 1, 2025, (ii) immediately prior
to the closing of an IPO, (iii) upon occurrence of a deemed Liquidation event